Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 92

1.

Probiotic Supplementation in Patients with Alzheimer's Dementia - An Explorative Intervention Study.

Leblhuber F, Steiner K, Schuetz B, Fuchs D, Gostner JM.

Curr Alzheimer Res. 2018;15(12):1106-1113. doi: 10.2174/1389200219666180813144834.

PMID:
30101706
2.

Commentary: Effect of Probiotic Supplementation on Cognitive Function and Metabolic Status in Alzheimer's Disease: A Randomized, Double-Blind and Controlled Trial.

Leblhuber F, Egger M, Schuetz B, Fuchs D.

Front Aging Neurosci. 2018 Mar 6;10:54. doi: 10.3389/fnagi.2018.00054. eCollection 2018. No abstract available.

3.

Lowered Levels of Carbonyl Proteins after Vitamin B Supplementation in Patients with Mild Cognitive Impairment and Alzheimer's Disease.

Rommer PS, Fuchs D, Leblhuber F, Schroth R, Greilberger M, Tafeit E, Greilberger J.

Neurodegener Dis. 2016;16(3-4):284-9. doi: 10.1159/000441565. Epub 2015 Nov 21.

PMID:
26587902
4.

Elevated fecal calprotectin in patients with Alzheimer's dementia indicates leaky gut.

Leblhuber F, Geisler S, Steiner K, Fuchs D, Schütz B.

J Neural Transm (Vienna). 2015 Sep;122(9):1319-22. doi: 10.1007/s00702-015-1381-9. Epub 2015 Feb 14.

PMID:
25680441
5.

Activated immune system and inflammation in healthy ageing: relevance for tryptophan and neopterin metabolism.

Capuron L, Geisler S, Kurz K, Leblhuber F, Sperner-Unterweger B, Fuchs D.

Curr Pharm Des. 2014;20(38):6048-57. Review.

PMID:
24641220
6.

Immune activation in patients with Alzheimer's disease is associated with high serum phenylalanine concentrations.

Wissmann P, Geisler S, Leblhuber F, Fuchs D.

J Neurol Sci. 2013 Jun 15;329(1-2):29-33. doi: 10.1016/j.jns.2013.03.007. Epub 2013 Apr 6.

PMID:
23566485
7.

Cognition, gender, and functional abilities in Alzheimer's disease: how are they related?

Benke T, Delazer M, Sanin G, Schmidt H, Seiler S, Ransmayr G, Dal-Bianco P, Uranüs M, Marksteiner J, Leblhuber F, Kapeller P, Bancher C, Schmidt R.

J Alzheimers Dis. 2013;35(2):247-52. doi: 10.3233/JAD-122383.

PMID:
23388173
8.

Driving cessation and dementia: results of the prospective registry on dementia in Austria (PRODEM).

Seiler S, Schmidt H, Lechner A, Benke T, Sanin G, Ransmayr G, Lehner R, Dal-Bianco P, Santer P, Linortner P, Eggers C, Haider B, Uranues M, Marksteiner J, Leblhuber F, Kapeller P, Bancher C, Schmidt R; PRODEM Study Group.

PLoS One. 2012;7(12):e52710. doi: 10.1371/journal.pone.0052710. Epub 2012 Dec 26.

9.

Vitamin D and tryptophan concentrations in patients with Alzheimer's disease.

Leblhuber F, Schneider A, Schroecksnadel S, Brunschütz D, Steiner K, Fuchs D.

Int J Geriatr Psychiatry. 2013 Feb;28(2):216-7. doi: 10.1002/gps.3810. No abstract available.

PMID:
23296838
10.

Placebo effect characteristics observed in a single, international, longitudinal study in Huntington's disease.

Cubo E, González M, del Puerto I, de Yébenes JG, Arconada OF, Gabriel y Galán JM; European Huntington's Disease Initiative Study Group.

Mov Disord. 2012 Mar;27(3):439-42. doi: 10.1002/mds.24062. Epub 2011 Dec 9.

PMID:
22162184
11.

Polyneuropathy and dementia in old age: common inflammatory and vascular parameters.

Leblhuber F, Schroecksnadel K, Beran-Praher M, Haller H, Steiner K, Fuchs D.

J Neural Transm (Vienna). 2011 May;118(5):721-5. doi: 10.1007/s00702-011-0579-8. Epub 2011 Feb 1.

PMID:
21286925
12.

Carbonyl proteins as a clinical marker in Alzheimer's disease and its relation to tryptophan degradation and immune activation.

Greilberger J, Fuchs D, Leblhuber F, Greilberger M, Wintersteiger R, Tafeit E.

Clin Lab. 2010;56(9-10):441-8.

PMID:
21086789
13.

Topiramate Treatment of Essential Tremor in a Patient with Cognitive Deficits.

Leblhuber F, Steiner K.

Case Rep Neurol. 2010 Jan 15;2(1):1-4.

14.

[Consensus statement "Dementia 2010" of the Austrian Alzheimer Society].

Schmidt R, Marksteiner M, Dal-Bianco P, Ransmayr G, Bancher C, Benke T, Wancata J, Fischer P, Leblhuber CF, Psota G, Ackerl M, Alf C, Berek K, Croy A, Delazer M, Fasching P, Frühwald T, Fruhwürth G, Fuchs-Nieder B, Gatterer G, Grossmann J, Hinterhuber H, Iglseder B, Imarhiagbe D, Jagsch C, Jellinger K, Kalousek M, Kapeller P, Ladurner G, Lampl C, Lechner A, Lingg A, Nakajima T, Rainer M, Reisecker F, Spatt J, Walch T, Uranüs M, Walter A.

Neuropsychiatr. 2010;24(2):67-87. German.

PMID:
20605003
15.

Weight loss in Huntington disease increases with higher CAG repeat number.

Aziz NA, van der Burg JM, Landwehrmeyer GB, Brundin P, Stijnen T; EHDI Study Group, Roos RA.

Neurology. 2008 Nov 4;71(19):1506-13. doi: 10.1212/01.wnl.0000334276.09729.0e.

PMID:
18981372
16.

Malondialdehyde, carbonyl proteins and albumin-disulphide as useful oxidative markers in mild cognitive impairment and Alzheimer's disease.

Greilberger J, Koidl C, Greilberger M, Lamprecht M, Schroecksnadel K, Leblhuber F, Fuchs D, Oettl K.

Free Radic Res. 2008 Jul;42(7):633-8. doi: 10.1080/10715760802255764.

PMID:
18654878
17.

Value of cerebral blood flow quantification in the diagnosis of dementia.

Zaknun JJ, Leblhuber F, Schücktanz H.

Nucl Med Commun. 2008 Mar;29(3):260-9. doi: 10.1097/MNM.0b013e3282f38f8f.

PMID:
18349797
18.

Homocysteine but not neopterin declines in demented patients on B vitamins.

Frick B, Gruber B, Schroecksnadel K, Leblhuber F, Fuchs D.

J Neural Transm (Vienna). 2006 Nov;113(11):1815-9. Epub 2006 Sep 21.

PMID:
16988797
19.

Increased brain levels of 4-hydroxy-2-nonenal glutathione conjugates in severe Alzheimer's disease.

Völkel W, Sicilia T, Pähler A, Gsell W, Tatschner T, Jellinger K, Leblhuber F, Riederer P, Lutz WK, Götz ME.

Neurochem Int. 2006 Jun;48(8):679-86. Epub 2006 Feb 17.

PMID:
16483694
20.

Association of hyperhomocysteinemia in Alzheimer disease with elevated neopterin levels.

Schroecksnadel K, Leblhuber F, Frick B, Wirleitner B, Fuchs D.

Alzheimer Dis Assoc Disord. 2004 Jul-Sep;18(3):129-33.

PMID:
15494618

Supplemental Content

Loading ...
Support Center